Success Metrics

Completion Rate
0%(0/2)
Active Trials
3(50%)
Terminated
2(33%)

Phase Distribution

Ph phase_1
1
17%
Ph phase_3
1
17%
Ph phase_2
2
33%
Ph phase_4
1
17%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Terminated(2)
Other(1)

Detailed Status

Recruiting2
Terminated2
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)

Trials by Status

active_not_recruiting117%
unknown117%
recruiting233%
terminated233%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_2

Ferumoxytol-enhanced Magnetic Resonance Venography in Patients With Venous Diseases

NCT07452250
recruitingphase_2

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

NCT05340465
active_not_recruitingphase_1

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

NCT04900792
terminatedphase_3

Ferumoxytol-enhanced Magnetic Resonance Imaging

NCT06348524
unknown

Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers

NCT04682847
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07452250Phase 2

Ferumoxytol-enhanced Magnetic Resonance Venography in Patients With Venous Diseases

Recruiting
NCT05340465Phase 2

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

Recruiting
NCT04900792Phase 1

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

Active Not Recruiting
NCT06348524Phase 3

Ferumoxytol-enhanced Magnetic Resonance Imaging

Terminated
NCT04682847

Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers

Unknown
NCT04080908Phase 4

Study to Assess Feasibility and Safety of Iron Repletion With Feraheme in Iron Deficient Patients With Durable Ventricular Assist Device Support

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6